Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20879664 | 0.86 | KDM5B (0.43) | KDM5BFGFR1FLT3FGFR2FGFR4 | |
| SCHEMBL16896617 | 0.84 | KDM5B (0.42) | KDM5BFGFR1FLT3FGFR2FGFR4 | |
| SCHEMBL31434668 | 0.82 | KDM5B (0.36) | KDM5BNLRP3FGFR1FLT3FGFR2 | |
| SCHEMBL31434774 | 0.81 | FLT3 (0.38) | KDM5BNLRP3FGFR1FLT3FGFR2 | |
| SCHEMBL31434617 | 0.81 | FGFR1 (0.37) | KDM5BNLRP3FGFR1FLT3FGFR2 | |
| SCHEMBL31434719 | 0.81 | FGFR1 (0.37) | KDM5BNLRP3FGFR1FLT3FGFR2 | |
| SCHEMBL13035463 | 0.79 | OGA (0.45) | KDM5BCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL21070701 | 0.79 | NLRP3 (0.41) | NLRP3FGFR2NPC1CYP1A2HPGD | |
| SCHEMBL24418198 | 0.76 | P2RY12 (0.40) | KDM5BFGFR1FLT3FGFR2FGFR4 | |
| SCHEMBL22781038 | 0.75 | KDM5B (0.43) | KDM5BFGFR1FLT3FGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361244-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2025-11-27 | — | — | US | disclosed |
| US-12410193-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2025-09-09 | — | — | US | disclosed |
| US-20240294547-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-09-05 | — | — | US | disclosed |
| US-11981685-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2024-05-14 | — | — | US | disclosed |
| EP-4353324-A2 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | Aurigene Oncology Limited (IN) | 2024-04-17 | — | — | EP | disclosed |
| US-20230331740-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-10-19 | — | — | US | disclosed |
| US-11691987-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-07-04 | — | — | US | disclosed |
| CN-111362966-B | Bicyclic heterocyclic derivatives as IRAK4 inhibitors | 奥列基因发现技术有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20220056046-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2022-02-24 | — | — | US | disclosed |
| US-10995100-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-05-04 | — | — | US | disclosed |
| US-10160753-B2 | Indazole compounds as IRAK4 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-12-25 | — | — | US | disclosed |
| EP-3094329-B1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2018-09-26 | — | — | EP | disclosed |
| US-20180022758-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-01-25 | — | — | US | disclosed |
| US-9732095-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-08-15 | — | — | US | disclosed |
| US-20160340366-A1 | BICYCLIC HETEROCYCLYL DERIVATES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2016-11-24 | — | — | US | disclosed |
| EP-3094329-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2016-11-23 | — | — | EP | disclosed |
| EP-3092226-A1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2016-11-16 | — | — | EP | disclosed |
| US-20160326151-A1 | Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-11-10 | — | — | US | disclosed |
| WO-2015104688-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015104662-A1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691987-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | KDM5B 813/4885NLRP3 13/4885FGFR1 1414/4885 |
| US-20240294547-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | KDM5B 783/4885NLRP3 13/4885FGFR1 1612/4885 |
| US-11981685-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | KDM5B 783/4885NLRP3 13/4885FGFR1 1612/4885 |
| US-20160340366-A1 | BICYCLIC HETEROCYCLYL DERIVATES AS IRAK4 INHIBITORS | IRAK4, IRAK1, IRAK3 | KDM5B 684/4885NLRP3 16/4885FGFR1 709/4885 |
| US-20220056046-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | KDM5B 813/4885NLRP3 13/4885FGFR1 1414/4885 |
| US-20180022758-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | KDM5B 813/4885NLRP3 13/4885FGFR1 1414/4885 |
| US-10160753-B2 | Indazole compounds as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | KDM5B 521/4885NLRP3 15/4885FGFR1 1210/4885 |
| US-20160326151-A1 | Indazole Compounds as IRAK4 Inhibitors | IRAK4, IRAK3, IRAK1 | KDM5B 521/4885NLRP3 15/4885FGFR1 1210/4885 |
| US-12410193-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | KDM5B 783/4885NLRP3 13/4885FGFR1 1612/4885 |
| US-20230331740-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | KDM5B 783/4885NLRP3 13/4885FGFR1 1612/4885 |
| US-10995100-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | KDM5B 813/4885NLRP3 13/4885FGFR1 1414/4885 |
| US-20250361244-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | KDM5B 783/4885NLRP3 13/4885FGFR1 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.